General Comments / Chat, page-11113

agree mate, at the moment ethics and governance are ultimately out of RACs hands, I believe they can be as short as a few weeks or as long as a few months to come through however this could be different overseas? so we’ve already got a few irons in the fire which is a great hedge. As others have said dosing will be a critical milestone met, and ultimately no issues with that should see this re rate significantly in anticipation of data, which with open label could come anytime. We all know the PK/PD is the same, we know the FDA now recognises this with two recent announcements and we have the most recent Sheba 2 data. We all probably say this every year but I think for once I can say it and mean it, next year will be the big one for us, it’s been a long frustrating hold for those holding from circa 2020 but we’re almost there. Once we have proof of concept strictly IMO I think all bets are off, I don’t see us lasting out much longer, the only grey area I have personally or caveat to this, is how do we bridge the gap between the current SP and what would be reasonable value for proof of concept CP. some mention licensing etc I’m not really sure what it would be, love to hear more thoughts on this from those more experienced. Personally although low, I would like to see $8 - $10 + with early readouts but I’m not sure how realistic this is given the aussie market struggles to price bio. FYI, this is not my price target, I’m talking strictly a market SP based off what we have and factoring in the markets inability to value fundamentals correctly.
cheers